Hostname: page-component-78c5997874-xbtfd Total loading time: 0 Render date: 2024-11-13T05:09:36.137Z Has data issue: false hasContentIssue false
  • English
  • Français

Powder diffraction data for methylenedioxymethylamphetamine hydrochloride monohydrate (MDMA.HCl.H2O, Ecstasy hydrate)

Published online by Cambridge University Press:  30 November 2012

D. F. Rendle  and
E. J. Glazier
D. F. Rendle*
Affiliation:
9 Wiltshire Drive, Wokingham, Berkshire RG40 1TQ, United Kingdom
E. J. Glazier
Affiliation:
9 Wiltshire Drive, Wokingham, Berkshire RG40 1TQ, United Kingdom
*
a)Author to whom correspondence should be addressed. Electronic mail: d.rendle@virgin.net
Get access Rights & Permissions [Opens in a new window]

Abstract

Powder diffraction data are presented for 3,4-methylenedioxymethylamphetamine hydrochloride monohydrate, the hydrated form of MDMA.HCl, the drug of abuse commonly known as Ecstasy. Samples of pure MDMA.HCl were recrystallized from a variety of solvents, and powder diffraction patterns of the resulting products recorded. Data were collected at room temperature using iron-filtered CoKα radiation.

Keywords

methylenedioxymethylamphetamine hydrochloride monohydrateEcstasyMDMA.HCl.H2OforensicdrugXRD
Type
New Diffraction Data
Information
Powder Diffraction , Volume 27 , Issue 4 , December 2012 , pp. 263 - 265
Copyright
Copyright © International Centre for Diffraction Data 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Boultif, A. and Louer, D. (2004). “Powder pattern indexing with the dichotomy method,” J. Appl. Cryst. 37, 724–731.CrossRefGoogle Scholar
ICDD (2012). PDF-4/Organics 2012 (Database), edited by Kabekkodu, S. (International Centre for Diffraction Data, Newtown Square, PA, USA).Google Scholar
McMurdie, H. F., Morris, M. C., Evans, E. H., Paretzkin, B., and Wong-Ng, W. (1986). “Methods of producing standard X-ray diffraction patterns,” Powder Diffr. 1, 40–43.CrossRefGoogle Scholar
Morimoto, B. H., Lovell, S., and Kahr, B. (1998). “Ecstasy: 3,4-methylenedioxymethylamphetamine (MDMA),” Acta Crystallogr., Sect. C: Cryst. Struct. Commun. 54, 229–331.CrossRefGoogle Scholar
Shulgin, A. T. (1986). “The background and chemistry of MDMA,” J. Psychoactive Drugs 18, 291–304.CrossRefGoogle ScholarPubMed
Shulgin, A. T. and Shulgin, A. (1992). PiKHaL (Phenethylamines I Have Known and Loved): A Chemical Love Story (Transform Press, Berkeley). (http://www.erowid.org/library/books_online/pihkal/pihkal.shtml) #109 MDMA; MDM; ADAM; Ecstasy; 3,4-methylenedioxy-N-methylamphetamine.Google Scholar
Smith, G. S. and Snyder, R. L. (1979). “F(n): a criterion for rating powder diffraction patterns and evaluating the reliability of powder pattern indexing,” J. Appl. Cryst. 12, 60–65.CrossRefGoogle Scholar
Zapata-Torres, G., Cassels, B. K., Parra-Mouchet, J., Mascarenhas, Y. P., Ellena, J., and De Araujo, A. S. (2008). “Quantum-chemical, NMR, and X-ray diffraction studies on (±)-1-[3,4-(methylenedioxy)phenyl]-2-methylaminopropane,” J. Mol. Graph. Model. 26, 1296–1305.CrossRefGoogle ScholarPubMed
Supplementary material: File

Rendle supplementary material

Rendle supplementary material

Download Rendle supplementary material(File)
File 34.3 KB